These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10022531)

  • 1. Bone marrow stromal cell-mediated gene therapy for hemophilia A: in vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648.
    Chiang GG; Rubin HL; Cherington V; Wang T; Sobolewski J; McGrath CA; Gaffney A; Emami S; Sarver N; Levine PH; Greenberger JS; Hurwitz DR
    Hum Gene Ther; 1999 Jan; 10(1):61-76. PubMed ID: 10022531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Human factor VIII expression in retrovirus vector-transduced bone marrow stromal cells].
    Guo X; Wang H; Chu H
    Zhonghua Xue Ye Xue Za Zhi; 2001 Sep; 22(9):461-3. PubMed ID: 11758224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow stromal cells as targets for gene therapy of hemophilia A.
    Chuah MK; Brems H; Vanslembrouck V; Collen D; VandenDriessche T
    Hum Gene Ther; 1998 Feb; 9(3):353-65. PubMed ID: 9508053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice.
    Chuah MK; Van Damme A; Zwinnen H; Goovaerts I; Vanslembrouck V; Collen D; VandenDriessche T
    Hum Gene Ther; 2000 Mar; 11(5):729-38. PubMed ID: 10757352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats.
    Van Damme A; Chuah MK; Dell'accio F; De Bari C; Luyten F; Collen D; VandenDriessche T
    Haemophilia; 2003 Jan; 9(1):94-103. PubMed ID: 12558785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
    Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
    J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice.
    Kikuchi J; Mimuro J; Ogata K; Tabata T; Ueda Y; Ishiwata A; Kimura K; Takano K; Madoiwa S; Mizukami H; Hanazono Y; Kume A; Hasegawa M; Ozawa K; Sakata Y
    J Gene Med; 2004 Oct; 6(10):1049-60. PubMed ID: 15386735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice.
    Nguyen GN; Lindgren JR; Seleme MC; Kafle S; Zander CB; Zheng XL; Sabatino DE
    J Thromb Haemost; 2023 Aug; 21(8):2101-2113. PubMed ID: 37080538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
    Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
    Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retroviral vector-modified bone marrow stromal cells secrete biologically active factor IX in vitro and transiently deliver therapeutic levels of human factor IX to the plasma of dogs after reinfusion.
    Cherington V; Chiang GG; McGrath CA; Gaffney A; Galanopoulos T; Merrill W; Bizinkauskas CB; Hansen M; Sobolewski J; Levine PH; Greenberger JS; Hurwitz DR
    Hum Gene Ther; 1998 Jul; 9(10):1397-407. PubMed ID: 9681411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained expression of human factor VIII in mice using a parvovirus-based vector.
    Chao H; Mao L; Bruce AT; Walsh CE
    Blood; 2000 Mar; 95(5):1594-9. PubMed ID: 10688813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.
    McIntosh J; Lenting PJ; Rosales C; Lee D; Rabbanian S; Raj D; Patel N; Tuddenham EG; Christophe OD; McVey JH; Waddington S; Nienhuis AW; Gray JT; Fagone P; Mingozzi F; Zhou SZ; High KA; Cancio M; Ng CY; Zhou J; Morton CL; Davidoff AM; Nathwani AC
    Blood; 2013 Apr; 121(17):3335-44. PubMed ID: 23426947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice.
    Xu L; Mei M; Ma X; Ponder KP
    J Thromb Haemost; 2007 Sep; 5(9):1805-12. PubMed ID: 17596134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
    Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
    N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A.
    Chuah MK; VandenDriessche T; Morgan RA
    Hum Gene Ther; 1995 Nov; 6(11):1363-77. PubMed ID: 8573610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic levels of human factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A.
    García-Martín C; Chuah MK; Van Damme A; Robinson KE; Vanzieleghem B; Saint-Remy JM; Gallardo D; Ofosu FA; Vandendriessche T; Hortelano G
    J Gene Med; 2002; 4(2):215-23. PubMed ID: 11933222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells.
    Moayeri M; Ramezani A; Morgan RA; Hawley TS; Hawley RG
    Mol Ther; 2004 Nov; 10(5):892-902. PubMed ID: 15509507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustaining expression of B domain-deleted human factor VIII mediated by using lentiviral vectors in NOD/SCID mouse.
    Li YJ; Chen C; Zeng LY; Cao J; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):658-63. PubMed ID: 22739177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells.
    Hurwitz DR; Kirchgesser M; Merrill W; Galanopoulos T; McGrath CA; Emami S; Hansen M; Cherington V; Appel JM; Bizinkauskas CB; Brackmann HH; Levine PH; Greenberger JS
    Hum Gene Ther; 1997 Jan; 8(2):137-56. PubMed ID: 9017418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut epithelial cells as targets for gene therapy of hemophilia.
    Lozier JN; Yankaskas JR; Ramsey WJ; Chen L; Berschneider H; Morgan RA
    Hum Gene Ther; 1997 Aug; 8(12):1481-90. PubMed ID: 9287148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.